Confirmed Exhibitors
Exhibit Hours
- Friday 25 October: 19:00 – 21:00 (Welcome Reception)
- Saturday 26 October: 10:30 – 16:15
- Sunday 27 October: 10:30 – 16:15
- Monday 28 October: 10:30 – 16:15
Confirmed Exhibitors
We would like to thank the following companies for their support.
EXHIBITORS
Annexon Biosciences is a late-stage biopharmaceutical company utilizing a distinct approach to stop C1q and all inflammatory aspects of classical complement pathway activation. Soley focused on targeting C1q, Annexon is developing a pipeline of therapeudics designed to provide meaningful benifits across multiple complement-mediated diseases of the body, brain and eye.
Learn more at www.annexonbio.com.
Biogen | Booth #205
At Biogen, we care deeply about making a difference and are humbled by the opportunity to change lives. Our 45-plus years of scientific expertise in neuroscience have helped to bring options to the lives of people living with neurological and neurodegenerative diseases while advancing a pipeline of potential novel therapies. Learn more at www.biogen.com.au
ICNMD 2026 | Booth #202
The journey was long and thorough but we have come to the end and have finally confirmed the host city for ICNMD 2026. The winner is Florence, Italy!
We are excited to be partnering with the Italian Society of Neurology (SIN) in hosting what will be a fantastic congress in 2026. Please stay tuned to our website for more updates as we look to host a great congress in Perth in 2024 and bring that momentum to Italy in 2026. (icnmd.org/icnmd-2026)
IOS Press | Table #A
Explore the IOS Press Neurodegenerative Disorders Journals Collection at ICNMD.Dive into the forefront of neurodegenerative disease research with the IOS Press Neurodegenerative Disorders Journals Collection. This comprehensive collection encompasses premier, peer-reviewed journals dedicated to pushing the boundaries of our understanding, improving patient care, and paving the way towards a cure for neurodegenerative disorders.(www.iospress.com/neurodegen)
iThera Medical | Booth #307
iThera Medical develops and markets optoacoustic imaging (OAI) systems for preclinical and clinical research. OAI utilizes the photoacoustic effect to visualize and quantify optical contrast. In the context of neuromuscular diseases, OAI has so far shown the potential to assess changes in molecular muscle tissue composition related to disease progression in DMD, SMA, FSHD, and Pompe disease. Learn more at www.ithera-medical.com
Janssen Asia Pacific | Booth #200
Janssen is now Johnson & Johnson Innovative Medicine. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented and cured, treatments are smarter and less invasive—and solutions are personal.
Learn more at www.janssen.com.
Janssen Australia, Ltd., a Johnson & Johnson company
Janssen Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd.
Medison | Booth #403
Medison is a global pharma company focused on providing access to highly innovative therapies in international markets, helping to save and improve the lives of patients suffering from the most challenging diseases.
Merck Healthcare | Booth #208
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company’s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Learn more at www.merckgroup.com.
MGBase Registry | Table #401
MGBase is the first global, observational registry dedicated to collecting de-identified data from patients diagnosed with myasthenia gravis. It provides a free research platform for clinicians to evaluate real-world outcomes data through collaborative, international research with the aim to advance myasthenia research and improve quality of patient care and outcomes.
Learn more at www.mgbase.org.
NADMED Ltd | Booth #305
NADMED, a startup based in Finland, specializes in innovative NAD measurement technologies. Spun out from the Anu Wartiovaara lab at the University of Helsinki, NADMED supports personalized medicine in e.g. neuromuscular diseases. Over 80 companies and research groups globally have adopted the rapid NADMED method, which offers accuracy comparable to mass spectrometry. Learn more at www.nadmed.com.
Novartis | Booth #404
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Learn more at www.novartis.com.
Takeda | Booth #209
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. (takeda.com)
UCB | Booth #301
UCB, headquartered in Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. (www.ucb.com)